摘要
目的探讨阿维A与甲氨蝶呤联合治疗难治性中重度银屑病的疗效及安全性。方法阿维A与甲氨蝶呤联合治疗12例难治性中重度银屑病患者24周,评估治疗期间治疗效果并监测用药不良反应。结果所有患者在24周治疗期内PASI评分逐渐下降(P<0.05),治疗16周时,达到PASI 75的患者占50.00%,达到PASI50占83.33%;24周时,PASI 50者为100%,PASI 75者为91.67%,所有患者均未发现明显不良反应。结论阿维A与MTX联合治疗难治性中重度银屑病的临床疗效明显,未发现不良反应。
Objective To evaluate the efficacy and safety of acitretin combined with methotrex- ate in treatment of refractory moderate to severe psoriasis vulgaris. Methods Twelve patients with moderate to severe psoriasis who were resistant to acitretin or methotrex- ate monotherapy were treated with acitretin combined with rnethotrexate for 24 weeks. The therapeutic effect was observed and adverse reactions of the multitherapy were monitored during tile 24 weeks of treatment. Results The PASI scoce decreased in all patients during 24-week treatment （P 〈 0.05）. Specifically, 50% achieved PASI 75 and 83.3% achieved PASI 50 after 16 weeks of treatment. All patients showed re- markable curative response （100% patients with PASI 50, vs. 91.67% with PASI 75）, at 24 weeks of treatment, and no adverse reactions were reported. Conclusion Acitretin combined with methotrexate is effective in the treatment of refractory mod- erate to severe psoriasis vulgaris and the adverse reactions of the muhitherapy are not noted.
作者
陈慧姮
梁晓冬
邓婕
薛如君
梁景耀
叶瑞贤
张锡宝
CHEN Huiheng;LIANG Xiaodong;DENG Jie;XUE Rujun;LIANG Jingyao;YE Ruixian;ZHANG Xibao(Institute of Dermatology, Gu, angzhou Medical University/Guangzhou Institute of Dermatology, Guangzhou 510095, China)
出处
《中国皮肤性病学杂志》
CAS
CSCD
北大核心
2018年第5期610-614,共5页
The Chinese Journal of Dermatovenereology
基金
广东省自然科学基金(2016A030313471)
关键词
阿维A
甲氨蝶呤
银屑病
难治性
联合治疗
安全性
Acitretin
Methotrexate
Psoriasis
Treatment-resistant
Combined theraphy
Safety
